Home > EURETINA Highlights
    • FILTER YOUR SEARCH
    Speciality:
    More Specialities

    • EURETINA Highlights

    Corneal Disorders
    Sunil Shah, EURETINA 2020 – Khmer Sight Foundation and Photon Ultraviolet C Device (Part 2)

    It was a pleasure to catch up with our Editorial Board member, Prof. Sunil Shah (Birmingham and Midland Eye Centre, Birmingham, UK), who explained the impact of the Photon Ultraviolet C (UVC) device that he has developed. Questions Could you give us an overview of the health burden of corneal infections in developing countries? (00:08) […]

    Corneal Disorders
    Sunil Shah, EURETINA 2020 – Khmer Sight Foundation and Photon Ultraviolet C Device (Part 1)

    It was a pleasure to catch up with our Editorial Board member, Prof. Sunil Shah (Birmingham and Midland Eye Centre, Birmingham, UK), who updated us on the aims of the Khmer Sight Foundation. Questions Could you tell us a little about The Khmer Sight Foundation and its objectives? (00:09) How did you become involved with […]

    Macular Degeneration
    Anat Loewenstein, EURETINA 2020 – The Importance of Home Monitoring

    It was a pleasure to catch up with our Editorial Board member, Prof. Anat Loewenstein (Tel Aviv Medical Center, Israel), who talked to us about the importance of home monitoring in wet age-related macular degeneration. How has the COVID-19 pandemic affected the management of patients with wet age-related macular degeneration (AMD)? (0:10) How can home […]

    Retina/Vitreous
    Tommaso Rossi, EURETINA 2020 – Novel Instrument for Internal Limiting Membrane

    We were delighted to catch up with Prof. Tommaso Rossi, who talked us through his presentation at EURETINA 2020 concerning a novel instrument for internal limiting membrane, amniotic and retinal flap manipulation. Questions What is the rationale for the use of amniotic membrane grafts in vitreoretinal surgery, and in what ophthalmic indications are they used? […]

    Retina/Vitreous
    Peter Stalmans, EURETINA 2020 – End-stage Retinitis Pigmentosa Patients Implanted with 3D–neural Interface Retinal Prosthesis

    Prof. Peter Stalmans (University Hospitals, Leuven, Belgium) talked us through his presentation at EURETINA on first reported clinical results from end-stage retinitis pigmentosa patients implanted with an innovative 3D neural interface retinal prosthesis. Questions     Could you give us an overview of advances in retinal prosthesis approaches in the treatment of advanced retinitis pigmentosa […]

    Retina/Vitreous
    Jost Jonas, EURETINA 2019 – Myopia: Epidemiology, Histology & Clinics

    It was fantastic to meet up with Jost Jonas (Ruprecht-Karls University) to discuss the Keynote Lecture ‘Myopia: Epidemiology, Histology & Clinics’ he presented at this year’s meeting. Support: No funding was received in the production of this video. Disclosures: Jost Jonas has nothing to disclose in relation to this video.

    Diabetic Retinopathy, Retina/Vitreous
    Michael Abramoff, EURETINA 2019 – AI-based diabetic retinopathy screening

    AI was a hot topic at ESRCS 2019, so we were honoured to meet with Michael Abramoff (University of Iowa) to discuss his latest research around an autonomous AI diagnostic system to assist with the diagnosis of diabetic retinopathy. Questions: 1. What are the limitations of current diagnosis of diabetic retinopathy? (0:04) 2. Could you […]

    Diabetic Macular Oedema, Retina/Vitreous
    Aditya Sudhalkar, EURETINA 2019 – Latest research on the use of intravitreal steroids in DME

    We met up with Aditya Sudhalkar at EURETINA 2019 to discuss his latest research into treating patients with intravitreal dexamethasone and to learn about his experiences as a rising-star in the field. Support: The production of this video was supported by Allergan, who had no involvement with the development of the content. Filmed at the […]

    Diabetic Macular Oedema, Retina/Vitreous
    Samantha Fraser-Bell, EURETINA 2019 – Results of the AUSSIDEX study

    Samantha Fraser-Bell (University of Sydney) caught up with us to share the latest results of the AUSSIDEX study, and discuss the real-world impact on patients with DME. Questions: 1. What are the main challenges you face when treating patients with diabetic macular oedema? (0:04) 2. Tell us about your current research in this area (0:31) […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72